

Express Mail Label:

EV 533189926 US

PTO/SB/17 (12-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2005☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$180.00)**Complete if Known**

Application Number	10/716890
Filing Date	11/19/2003
First Named Inventor	Zhaoning Zhu, et al.
Examiner Name	Ebenezer O. Sackey
Art Unit	1626
Attorney Docket No.	IN01535KB

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 19-0365 Deposit Account Name: Schering-Plough Corp.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
70	- 20 or HP =	x	=			
HP = highest number of total claims paid for, if greater than 20						
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)			
	- 3 or HP =	x	=			
HP = highest number of independent claims paid for, if greater than 3						

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
	- 100 =	/ 50 =	(round up to a whole number) x	=

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: IDS


\$180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 34,634	Telephone (908) 298-5068
Name (Print/Type)	Palaiyur S. Kalyanaraman	Date	06/30/2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT: IN01535KB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zhaoning Zhu, et al.

Serial No.: 10/716,890

Filed: 11/19/2003

For: **COMPOUNDS FOR THE TREATMENT :
OF INFLAMMATORY DISORDERS :**

Examiner: Ebenezer O. Sackey

Group Art Unit: 1626

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Amendment

INFORMATION DISCLOSURE STATEMENT

Sir:


Submitted herewith is Applicants' PTO-1449 form for the above-identified application. Also submitted herewith are copies of the Information Disclosure Statements from Applicants' parent Application Serial No. 10/323,511, filed December 19, 2002, the IDS that was filed, and the PTO-1449 from the IDS.

Since the cited references were cited in Applicants' parent Application, copies of the references are not being submitted herewith. The Examiner is requested to notify the undersigned if another copy of the references is desired.

Applicants request that the cited references be made of record in the above-identified Application.

Respectfully submitted,

Dated: 06/30/2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By: 
Name: Palaiyur S. Kalyanaraman
Reg. No.: 34,634
Attorney of Record
Telephone No.: (908) 298-5068

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

IN01535KB

10/716,890

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

Zhaoning Zhu et al.

FILING DATE:

11/19/2003

GROUP:

1626

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	4267333	05/12/81	Tsao			
	AB	3740412	06/19/73	E. Ullman et al.			
	AC	3997223	12/14/76	H. Feldman et al.			
	AD	4166452	09/04/79	C. D.J. Generales, Jr.			
	AE	4256108	03/17/81	F. Theeuwes			
	AF	4265874	05/05/81	Bonsen, et al.			
	AG	4431661	02/14/84	McKenzie et al.			
	AH	4435419	03/06/84	Epstein et al.			
	AI	4544665	10/10/85	Epstein et al.			
	AJ	5037853	08/06/91	Brooks et al.			
	AK	5089633	02/18/92	Powers et al.			
	AL	5114953	05/19/92	Galardy et al.			
	AM	5120752	06/09/92	Brooks et al.			
	AN	5256657	10/26/93	Singh et al.			
	AO	5455258	10/03/95	MacPherson et al.			
	AP	5506242	04/09/96	MacPherson et al.			
	AQ	5514716	05/07/96	Gowravaram et al.			
	AR	5552419	09/03/96	MacPherson et al.			
	AS	5594106	01/14/97	Black et al.			
	AT	5618844	04/08/97	Gowravaram et al.			
	AU	5646167	07/08/97	MacPherson et al.			
	AV	5665777	09/09/97	Fesik et al.			
	AW	5674901	10/07/97	Cook et al.			
	AX	5703092	12/30/97	Xue et al.			
	AY	5712300	01/27/98	Jacobsen			
	AZ	5753653	05/19/98	Bender et al.			
	BA	5770624	06/23/98	Parker et al.			
	BB	5804581	09/08/98	Wolanin et al.			
	BC	5817822	10/06/98	Nantermet et al.			
	BD	5830915	11/03/98	Pikul et al.			
	BE	5837696	11/17/98	Golub et al.			
	BF	5853977	12/29/98	Dalie et al.			
	BG	5856337	01/05/99	Okazoe et al.			
	BH	5962481	10/05/99	Levin et al.			
	BJ	5977408	11/02/99	Levin et al.			
	BK	5985900	11/16/99	Bender et al.			
	BL	6034096	03/07/00	Bertolini et al.			
	BM	6057336	05/02/00	Duane et al.			
	BN	6066633	05/23/00	De Nanteuil et al.			
	BO	6071903	06/06/00	Albright et al.			
	BP	6103739	08/15/00	Floyd et al.			
	BQ	6114361	09/05/00	Robinson et al.			
	BR	6153757	11/28/00	Zook et al.			
	BS	6172057	01/09/01	Venkatesan et al.			
	BT	6177077	01/23/01	Tobinick et al.			
	BU	6197791	03/06/01	Venkatesan et al.			
	BV	6200996	03/13/01	Levin et al.			
	BW	6225311	05/01/01	Levin et al.			
	BX	6277885	08/21/01	Levin et al.			
	BY	6294539	09/25/01	Lou et al.			
	BZ	6313123	11/06/01	Levin et al.			
	CA	6326516	12/04/01	Levin et al.			
	CB	6372747	04/16/02	Taveras et al.			
	CC	US2001/0046989	11/29/01	Levin et al.			



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB		SERIAL NO.: 10/716,890	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.			
				FILING DATE: 11/19/2003		GROUP: 1626	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	CD	AU534404 B	01/26/84	AUSTRALIA			
	CE	CA2166168 A1	06/29/96	CANADA	C07H	15/26	
	CF	CA2260337 A1	07/27/99	CANADA	C07C	311/46	
	CG	CA2281570 A1	09/17/98	CANADA	A61K	35/60	
	CH	DE19831980 A1	01/20/00	GERMANY	C07F	9/38	
	CI	EP00952148 A1	10/27/99	EUROPE	C07C	317/14	
	CJ	EP0097816 B1	05/18/88	EUROPE	B41J	5/28	
	CK	EP0887077A1	12/30/88	EUROPE	A61K	31/015	
	CL	EP1004578 A2	05/31/00	EUROPE	C07D	207/28	
	CM	EP1029851 A1	08/23/00	EUROPE	C07D	213/74	
	CN	EP1041072 A1	10/04/00	EUROPE	C07D	317/44	
	CO	EP1081137 A1	03/07/01	EUROPE	C07D	211/96	
	CP	EP498665 B1	04/24/96	EUROPE	C07C	259/06	
	CQ	EP574758 B1	09/09/98	EUROPE	C07D	209/48	
	CR	EP641323 A1	09/29/94	EUROPE	C07D	215/38	
	CS	EP667770 B1	03/19/97	EUROPE	A61K	31/16	
	CT	EP684240 B1	08/02/00	EUROPE	C07D	401/06	
	CU	EP757037 A2	02/05/97	EUROPE	C07C	311/42	
	CV	EP769947 B1	05/02/01	EUROPE	A61K	31/40	
	CW	EP780386 B1	10/02/02	EUROPE	C07D	309/08	
	CX	EP818442-A2	01/14/88	EUROPE	C07D	317/44	
	CY	EP818442-A3	12/30/88	EUROPE	C07C	317/44	
	CZ	EP863885 A2	05/22/97	EUROPE	C07D	413/12	
	DA	EP871439 A1	07/10/97	EUROPE	A61K	31/19	
	DB	EP877018 B1	05/02/03	EUROPE	C07C	311/19	
	DC	EP877019 B1	12/12/01	EUROPE	C07C	311/19	
	DD	EP895988 B1	05/22/02	EUROPE	C07C	311/19	
	DE	EP922702 A1	06/16/99	EUROPE	C07D	295/185	
	DF	FR2780402 A1	12/31/99	FRANCE	C07D	233/12	
	DG	FR2788525 A1	07/21/00	FRANCE	C07K	5/08	
	DH	GB2200628 A	08/10/88	UNITED KINGDOM	C07D	303/02	
	DI	GB2268934 A	01/26/94	UNITED KINGDOM	C07C	259/06	
	DJ	GB2333524 A	07/28/99	UNITED KINGDOM	C07D	213/75	
	DK	JP95002797	01/06/95	JAPAN	C07D	237/04	
	DL	JP98130217	05/19/98	JAPAN	C07C	237/22	
	DM	JP98204054	08/04/98	JAPAN	C07C	311/29	
	DN	JP98204059	08/04/98	JAPAN	C07D	209/10	
	DO	WO00/06560 A1	02/10/00	PCT	C07D	307/91	
	DP	WO00/06561 A1	02/10/00	PCT	C07D	307/91	
	DQ	WO00/09485 A1	02/24/00	PCT	C07D	211/96	
	DR	WO00/12082 A1	03/09/00	PCT	A61K	31/34	
	DS	WO00/12083 A1	03/09/00	PCT	A61K	31/34	
	DT	WO00/12466 A1	03/09/00	PCT	C07C	243/02	
	DU	WO00/12477 A1	03/09/00	PCT	C07D	211/96	
	DV	WO00/12478 A1	03/09/00	PCT	C07D	213/42	
	DW	WO00/15603 A1	03/23/00	PCT	C07C	233/60	
	DX	WO00/16766 A1	03/30/00	PCT	A61K	31/135	
	DY	WO00/24720 A1	05/04/00	PCT	C07D	249/08	
	DZ	WO00/32570 A1	06/08/00	PCT	C07C	311/49	
	EA	WO00/35885 A1	06/22/00	PCT	C07D	133/80	

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB		SERIAL NO.: 10/716,890		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.				
				FILING DATE: 11/19/2003		GROUP: 1626		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	EB	WO00/37433 A1	06/22/00	PCT	C07C	259/10		
	EC	WO00/40564 A1	07/13/00	PCT	C07D	223/16		
	ED	WO00/40576 A2	07/13/00	PCT	C07D	355/02		
	EE	WO00/40578 A1	07/13/00	PCT	C07D	403/12		
	EF	WO00/42436 A1	07/20/00	PCT	G01N	33/68		
	EG	WO00/44709 A2	08/03/00	PCT	C07C	311/00		
	EH	WO00/44711 A1	08/03/00	PCT	C07C	311/29		
	EI	WO00/44713 A1	08/03/00	PCT	C07C	317/44		
	EJ	WO00/44716 A1	08/03/00	PCT	C07C	323/49		
	EK	WO00/44723 A1	08/03/00	PCT	C07D	211/66		
	EL	WO00/44730 A1	08/03/00	PCT	C07D	243/14		
	EM	WO00/44740 A2	08/03/00	PCT	C07D	333/00		
	EN	WO00/44749 A1	08/03/00	PCT	C07D	471/04		
	EO	WO00/46189 A1	08/10/00	PCT	C07C	311/15		
	EP	WO00/46221 A1	08/10/00	PCT	C07D	415/12		
	EQ	WO00/50391 A1	08/31/00	PCT	C07C	311/21		
	ER	WO00/58278 A1	10/05/00	PCT	C07C	311/19		
	ES	WO00/58280 A1	10/05/00	PCT	C07C	311/29		
	ET	WO00/58304 A1	10/05/00	PCT	C07D	401/12		
	EU	WO00/59874 A1	10/12/02	PCT	C07C	259/06		
	EV	WO00/63165 A1	10/26/00	PCT	C07C	259/06		
	EW	WO00/63194 A1	10/26/00	PCT	C07D	271/06		
	EX	WO00/63197 A1	10/26/00	PCT	C07D	277/14		
	EY	WO00/69812 A1	11/23/00	PCT	C07C	259/06		
	EZ	WO00/69827 A1	11/23/00	PCT	C07D	215/22		
	FA	WO01/22952 A2	04/05/01	PCT	A61K	31/00		
	FB	WO01/30360 A1	05/03/01	PCT	A61K	31/70		
	FC	WO01/62704 A1	08/03/01	PCT	C07C	217/54		
	FD	WO01/67103 A1	09/13/01	PCT	G01N	33/53		
	FE	WO01/70673 A2	09/27/01	PCT	C07C	237/00		
	FF	WO01/70734 A2	09/27/01	PCT	C07D	401/12		
	FG	WO01/87870 A1	11/22/01	PCT	C07D	307/52		
	FH	WO02/04416 A2	01/17/02	PCT	C07D	207/00		
	FI	WO02/18326 A1	03/07/02	PCT	C07C	259/06		
	FJ	WO02/96426 A1	12/05/02	PCT	A61K	31/4709		
	FK	WO03/016248 A2	02/27/01	PCT	C07C			
	FL	WO03/024899 A2	03/27/03	PCT	C07C			
	FM	WO90/05719 A1	05/31/90	PCT	C07C	323/62		
	FN	WO93/07111 A1	04/15/93	PCT	C07C	49/753		
	FO	WO93/20047 A1	10/14/93	PCT	C07C	317/44		
	FP	WO94/00555 A2	01/06/94	PCT	C12N			
	FQ	WO94/21612 A1	09/29/94	PCT	C07D	215/38		
	FR	WO94/24140 A1	10/27/94	PCT	C07H	13/04		
	FS	WO94/27947 A1	12/08/94	PCT	C07C	47/47		
	FT	WO95/06031 A1	03/02/95	PCT	C07C	317/44		
	FU	WO95/09841 A1	04/13/95	PCT	C07C	323/60		
	FV	WO95/19956 A1	07/27/95	PCT	C07C	259/06		
	FW	WO95/19957 A1	07/27/95	PCT	C07C	259/06		

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB		SERIAL NO.: 10/716,890		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.				
				FILING DATE: 11/19/2003		GROUP: 1626		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	FX	WO95/19961 A1	07/27/95	PCT	C07C	323/41		
	FY	WO95/24501 A1	09/14/95	PCT	C12Q	1/37		
	FZ	WO95/29892 A1	11/09/95	PCT	C07D	207/327		
	GA	WO96/33166 A1	10/24/96	PCT	C07C	259/06		
	GB	WO96/33176 A1	10/24/96	PCT	C07D	235/16		
	GC	WO96/40204 A1	12/19/96	PCT	A61K	38/05		
	GD	WO97/03105 A1	01/30/97	PCT	C08G	65/22		
	GE	WO97/09066 A1	03/13/97	PCT	A61K	45/00		
	GF	WO97/12902 A1	04/10/97	PCT	C07K	5/03		
	GG	WO97/18188 A1	05/22/97	PCT	C07C	259/06		
	GH	WO97/18207 A2	05/22/97	PCT	C07D	413/12		
	GI	WO97/19053 A1	05/29/97	PCT	C07C	237/22		
	GJ	WO97/20824 A1	06/12/97	PCT	C07D	241/04		
	GK	WO97/22587 A1	06/26/97	PCT	C07D	213/42		
	GL	WO97/24117 A1	07/10/97	PCT	A61K	31/19		
	GM	WO97/32846 A1	09/12/97	PCT	C07D	207/26		
	GN	WO97/40031 A1	10/30/97	PCT	C07D	285/125		
	GO	WO97/42168 A1	11/13/97	PCT	C07C	323/22		
	GP	WO98/02557 A2	01/22/98	PCT	C12N	15/57		
	GQ	WO98/03164 A1	01/29/98	PCT	A61K	31/165		
	GR	WO98/03516 A1	01/29/98	PCT	C07F	9/30		
	GS	WO98/07697 A1	02/26/98	PCT	C07D	211/58		
	GT	WO98/08822 A1	03/05/98	PCT	C07D	239/04		
	GU	WO98/08823 A1	03/05/98	PCT	C07D	239/06		
	GV	WO98/08825 A1	03/05/98	PCT	C07D	241/04		
	GW	WO98/08827 A1	03/05/97	PCT	C07D	243/08		
	GX	WO98/09957 A1	03/12/98	PCT	C07D	307/91		
	GY	WO98/09961 A1	03/12/98	PCT	C07D	410/12		
	GZ	WO98/12211 A1	03/26/98	PCT	C07K	5/078		
	HA	WO98/13340 A1	04/02/98	PCT	C07C	317/44		
	HB	WO98/15525 A1	04/16/98	PCT	C07C	259/06		
	HC	WO98/16503 A2	04/23/98	PCT	C07C	311/00		
	HD	WO98/16506 A1	04/23/98	PCT	C07C	311/20		
	HE	WO98/16514 A1	04/23/98	PCT	C07D	215/54		
	HF	WO98/16520 A1	04/23/98	PCT	C07D	333/38		
	HG	WO98/17643 A1	04/30/98	PCT	C07D	207/327		
	HH	WO98/17655 A1	04/30/98	PCT	C07D	295/18		
	HI	WO98/22436 A1	05/28/98	PCT	C07D	323/56		
	HJ	WO98/23588 A1	06/04/98	PCT	C07D	209/48		
	HK	WO98/24759 A1	06/11/98	PCT	C07C	259/06		
	HL	WO98/27069 A1	06/25/98	PCT	C07D	241/04		
	HM	WO98/30541 A1	07/16/98	PCT	C07D	209/18		
	HN	WO98/30551 A1	07/16/98	PCT	C07D	267/00		
	HO	WO98/30566 A1	07/16/98	PCT	C07D	493/08		
	HP	WO98/32748 A1	07/30/98	PCT	C07D	295/22		
	HQ	WO98/33788 A1	08/06/98	PCT	C07D	309/12		
	HR	WO98/37877 A1	09/03/98	PCT	A61K	3/16		
	HS	WO98/38163 A1	09/03/98	PCT	C07D	323/60		

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB	SERIAL NO.: 10/716,890			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.				
				FILING DATE: 11/19/2003	GROUP: 1626			
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	HT	WO98/38167 A1	09/03/98	PCT	C07D	215/54		
	HU	WO98/38179 A1	09/03/98	PCT	C07D	277/46		
	HV	WO98/42662 A1	10/01/98	PCT	C07C	327/32		
	HW	WO98/43959 A1	10/08/98	PCT	C07D	215/22		
	HX	WO98/43963 A1	10/08/98	PCT	G01N	233/54		
	HY	WO98/45699 A1	10/15/98	PCT	C07C	30/56		
	HZ	WO98/46563 A1	10/22/98	PCT	C07C	323/41		
	IA	WO98/50348 A1	11/12/98	PCT	C07C	311/29		
	IB	WO98/52910 A1	11/26/98	PCT	C07D	233/22		
	IC	WO99/02510 A1	01/21/99	PCT	C07D	295/18		
	ID	WO99/06410 A1	02/11/99	PCT	C07D	495/04		
	IE	WO99/18074 A1	04/15/99	PCT	C07D	495/04		
	IF	WO99/18076 A1	04/15/99	PCT	C07D	207/27		
	IG	WO99/18079 A1	04/15/99	PCT	C07D	215/54		
	IH	WO99/19296 A1	04/22/99	PCT	C07C	231/12		
	II	WO99/24399 A1	05/22/99	PCT	C07C	233/63		
	IJ	WO99/24408 A1	05/20/99	PCT	C07D	311/04		
	IK	WO99/24419 A1	05/20/99	PCT	C07D	239/22		
	IL	WO99/31052 A1	06/24/99	PCT	C07C	333/60		
	IM	WO99/32413 A1	07/01/99	PCT	C03B	259/06		
	IN	WO99/32451 A1	07/01/99	PCT	C07D	37/014		
	IO	WO99/32452 A1	07/01/99	PCT	C07D	233/12		
	IP	WO99/37625 A1	07/29/99	PCT	C07D	243/14		
	IQ	WO99/32463 A1	07/01/99	PCT	C07D	273/00		
	IR	WO99/37635 A2	06/29/00	PCT	C12N	15/11		
	IS	WO99/38843 A1	08/05/99	PCT	C07C	317/44		
	IT	WO99/400800 A1	08/12/99	PCT	C07D	309/08		
	IU	WO99/42436 A1	08/26/99	PCT	C07C	239/14		
	IV	WO99/42443 A1	08/26/99	PCT	C07D	209/48		
	IW	WO99/52910 A1	10/11/99	PCT	C07D	493/08		
	IX	WO99/58528 A1	11/18/99	PCT	C07D	405/12		
	IY	WO99/58531 A1	11/18/99	PCT	C07D	417/12		
	IZ	WO99/61413 A1	12/02/99	PCT	C07C	259/06		
	JA	WO99/65867 A1	12/23/99	PCT	C07C	259/08		

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB	SERIAL NO.: 10/716,890
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.	
				FILING DATE: 11/19/2003	GROUP: 1626
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	JB	M. H. Rabinowitz et al., "Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor- α Converting Enzyme (TACE)", J Med Chem, 44 :4252-67 (2001)			
	JC	J. W. Skiles et al., "The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors" Current Medicinal Chem. 8 :425-474 (2001)			
	JD	R. Newton et al., "Biology of TACE Inhibition" Ann RheumDis 60 iii 25-iii32 Dis(2001)			
	JE	Delos Santos et al., "The Syntheses of 2,3,4,5-Tetrahydro-1H-[1,4] Benzodiazepine-3-Hydroxamic Acids as Matrix Metalloproteinase and TACE Inhibitors", Wyeth-Ayerst Research-			
	JF	A. K. Ghose et al., "Determination of Pharmacophoric Geometry for Collagenase Inhibitors Using a Novel Computational Method and Its Verification Using Molecular Dynamics, NMR, and X-ray Crystallography". J. Am. Chem. Soc'y 117 , 4671-4682 (1995)			
	JG	S. F. Martin et al., "Cyclopropanes as Conformationally Restricted Peptide Isosteres. Design and Synthesis of Novel Collagenase Inhibitors" Tetrahedron 49 :(17) 3521-32 (1993)			
	JH	R. A. Black., "Tumor Necrosis Factor- α Converting Enzyme", The International J. Biocem. Cell Biology. (2002) 34 (1): 1-5			
	JI	M. Moss et al., "TACE and other ADAM Proteases as Targets for Drug Discovery", Drug Discovery Today 6 (8):417-26 (2001)			
	JJ	Feldman et al, Lancet (1994) 344 ,1105			
	JK	L. S. Lohmander et al., "The Structure of Aggrecan Fragments in Human Synovial Fluid", Arthritis Rheum. 36 :(9) 1214-22 (1993)			
	JL	T. T. Macdonald et al., "Tumor Necrosis Factor-alpha and Interferon-gamma Production measured at the single cell level in normal and inflamed human intestine", Clin. Exp. Immunol. 81 :301-305 (1990)			
	JM	H. Mankin et al., "Biochemical and Metabolic Abnormalities in Articular Cartilage from Osteo-Arthritic Human Hips", J. Bone Joint Surg. 52A (1970) 424-34			
	JN	J. F. Woessner et al., "Collagenase and Collagenolytic Activity in Human Osteoarthritic Cartilage", Arthritis and Rheum. 26 (1), 63-68 (1983)			
	JO	J. F. Woessner et al., "Neutral Proteases Capable of Proteoglycan Digesting Activity in Osteoarthritic and Normal Human Articular Cartilage", Arthritis Rheum 27 :3, 305-312 (1984)			
	JP	R. C. Wahl et al., "Chapter 19. Biochemistry and Inhibition of Collagenase and Stromelysin", Ann. Rep. Med. Chem. 25 :177- 184			
	JQ	Gearing et al., Nature (1994) 370 , 555			
	JR	J. Higuchi et al., Pro-Drugs as Novel Delivery Systems (1987) Vol. 14 of the A.C.S. Symposium Series			
	JS	E. Roche (Ed.), Bioreversible Carriers in Drug Design (1987) Amer. Pharma. Assoc. and Pergannon Press			
	JT	S.M. Berge et al., "Pharmaceutical Salts", Journal of Pharm. Sciences 66 (1) 1-19 (1977)			
	JU	P. L. Gould, "Salt Selection for Basic Drugs", International J. of Pharmaceutics 33 :201-217 (1986)			
	JV	G. Kokotos and C. Noula, "Selective One-Pot Conversion of Carboxylic Acids into Alcohols", J. Org. Chem. 61 :6994-6996 (1996)			
	JW	F. J. Lotspeich, "The Reaction of Potassium Cyanide with p-Phenylsulfonylbenzyl Bromide", J. Chem. Soc., J. Org. Chem. 32 :12-74-1277 (1967)			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB	SERIAL NO.: 10/716,890
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.	
				FILING DATE: 11/19/2003	GROUP: 1626
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
JX	G. Kottirsch et al., "β-Aryl – Succinic Acid Hydroxamates as Dual Inhibitors of Matrix Metalloproteinases and Tumor Necrosis Factor Alpha Converting Enzyme", J. Med. Chem. 45:2289-2293 (2002)				
JY	F. Nelson et al., "The Therapeutic Potential of Small Molecule TACE Inhibitors", Exp. Opin. Invest. Drugs, 9(4):393-92 . (1999)				
JZ	J. Duan et al., "Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure-Activity Relationships", J. Med. Chem., 45:4954-4957 (2002)				
KA	D. Chantry, "Tumor Necrosis Factor Antagonists", Emerging Drugs, Annual Exec. Briefing 4: 5-13 . (1999)				
KB	G. Van Assche et al., "Anti-TNF Agents in Crohn's Disease" 9(1) Exp. Opin. Invest. Drugs 9(1):103-111 (2000)				
KC	A. Dove, "MMP Inhibitors: Glimmers of Hope Amidst Clinical Failures", Nature Medicine 8(2) (Feb. 2002) 95				
KD	C. Brou et al., "A Novel Proteolytic Cleavage Involved in Notch Signaling: The role of the Disintegrin – Metalloprotease TACE", Molecular Cell 5:207-216 (2000)				
KE	C. Xue et al., "Design, Synthesis, and Structure-Activity Relationships of Macrocyclic Hydrosanic Acids that Inhibit Tumor Necrosis Factor & Release In Vitro and In Vivo", J. Med. Chem. 44:2636-2660 (2001)				
KF	D. M. Skovronsky et al., "Neuronal Localization of the TNF α Converting Enzyme (TACE) in Brain Tissue and Its Correlation to Amyloid Plaques", J. Neurobiol 49:40-46 (2001)				
KG	E. Kleinman et al., "Striking Effect of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNFα Inhibitory Activity of Two Series of Rolipram Analogues: Implications for a New Active Site Model of PDE4", 41 J. Med. Chem. (Aug. 2, 2001) 2549-2502				
KH	S. Pikul, "Potent and Selective Carboxylic Acid-Based Inhibitors of Matrix Metalloproteinases", J. Med. Chem. 44(16) 2549-2502 (Aug. 2, 2001)				
KI	T. Hirata et al., "Discovery of Potent, Highly Selective, and Orally Active Propenohydroxamate TNF-α Converting Enzyme (TACE) Inhibitors" Abstract # MEDI 262, 222 nd National Meeting (ACS) Chicago				
KJ	Y. Tamura et al., "Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives", J. Med. Chem. 41:640-49 (1998)				
KL	J. S. Tullis et al., "The Development of New Carboxylic Acid-Based MMP Inhibitors Derived from a Cyclohexylglycine Scaffold", Bio. Org. Med. Chem. Letters. 11:1975-79 (2001)				
KM	R. Kiyama, "Homology Modeling of Gelatinase Catalytic Domains and Docking Simulations of Novel Sulfonamide Inhibitors", J. Med. Chem. 42:1723-38 (1999)				
KN	M. Whittaker et al., "Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors", Chem. Rev. 99:2735-76 (1999)				
KO	J. El Yazal et al., "Ab Initio Calculations of Proton Dissociation Energies of Zinc Ligands: Hypothesis of Imidazolate as Zinc Ligand in Proteins", J. Phys. Chem. B. 103: 8773-79 (1999)				
KP	B. Barlaam et al., "New α-Substituted Succinate-Based Hydroxamic Acids as TNFα Convertase Inhibitors", J. Med. Chem. 42:4890-4908 (1999)				
KQ	J. R. Doedens et al., "Stimulation-induced Down Regulation of Tumor Necrosis Factor-α Converting Enzyme", J. Biol. Chem. 275(19) 14598-14607 (May 12, 2000)				
KR	P. Reddy et al., "Functional Analysis of the Domain Structure of Tumor Necrosis Factor-α Converting Enzyme", J. Biol. Chem. 275(19) 14608-14614 (May 12, 2000)				
KS	N. Hooper et al., "Membrane Protein Secretases", BioChem. J., 321:265-79 (1977)				

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01535KB	SERIAL NO.: 10/716,890
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Zhaoning Zhu et al.	
				FILING DATE: 11/19/2003	GROUP: 1626
	KT	J. El Yazal, "Proton Dissociation Energies of Zinc-Coordinated Hydroxamic Acids and Their Relative Affinities for Zinc: Insight into Design of Inhibitors of Zinc-Containing Proteinases" J. Phys. Chem. B. 104 :6499-6504 (2000)			
	KU	T. Burton, "Research & Development: Abbott's Arthritis Drug Shows Promise, WSJ Says", Morning Highlight for June 13, 2001, Wall Street Journal			
	KV	A. Reichelt et al., "Design, Synthesis, and Evaluation of Matrix Metalloprotease Inhibitors Bearing Cyclopropane-Derived Peptidomimetics as P1' and P2' Replacements", J. Org. Chem. 67 :4062-75 (2002)			
	KW	PATENT ABSTRACTS OF JAPAN No. 018, No. 032 (C-1154), (1994-01-18) & JP 05 262698 A (Dainippon Ink & Chem Inc; Others: 01), (1993-10-12)			
	KX	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 3152815 XP002244521			
	KY	Anderson <i>et al.</i> , The Practice of Medicinal Chemistry (1996) Academic Press, N.Y.			
	KZ	Mankin <i>et al.</i> , Arthritis Rheum. 21 (1978) 761-66			
EXAMINER		DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					